News / Health

Race On to Develop New Antibiotics

Carbapenem-resistant Klebsiella pneumoniae bacteria
Carbapenem-resistant Klebsiella pneumoniae bacteria

Multimedia

Vidushi Sinha

Drug companies are struggling to develop new and more effective antibiotics to combat the growing worldwide threat from drug-resistant germs.  In this second of her 2-part report on "Battling Superbugs," we examine the looming public health danger, and the challenges drug companies face in bringing new antibiotics to market.

Medical experts watching the rising tide of drug-resistant bacteria have begun sounding the alarms.  They say life-threatening infections could jeopardize surgeries, cancer treatment, organ transplants, and many other specialized medical procedures.

And some warn that if new anti-microbial drugs are not developed within the next few years, billions of people will be left nearly defenseless against some lethal bacterial infections.

Such concerns have prompted the Infectious Disease Society of America (IDSA) to call for the development of 10 new antibiotic drugs by the year 2020, an initiative the group calls "10 by 20."

“The 10 by 20 initiative is IDSA’s challenge to the global community to come together to bring the right group of people together. People in government, industry, academia, policy makers to figure out the right combination of incentives that both will motivate companies who want to develop new antibiotics and also to find new ways to manage these products over time," said Robert Guidos, Vice President of IDSA.

Experts say that the hour of reckoning has arrived, and that if efforts to combat the problem are not launched now, dangerous diseases eradicated long ago could make a comeback.

Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention, shared that concern recently with Capitol Hill lawmakers. "If we don't improve our response to the public health problem of antibiotic resistance, we may enter a post- antibiotic world in which we will have few or no clinical interventions for some infections," he said.

Recent studies have shown that there are very few new antibiotics in the development pipeline that would work against lethal infections born out of bacterial resistance such as Methicillin-resistant Staphylococcus aureus, commonly known as MRSA, or carbapenem-resistant Klebsiella pneumoniae, or CRKP for short.

About 2 million MRSA infections have been reported in U.S. hospitals each year since 2002.

Barry Eisenstein is Vice President of Cubist, an American drug company with a new anti-MRSA drug in development, as well as many others.

He says neither the federal regulatory environment nor the pharmaceutical market are favorable for companies trying to develop antibiotics. “The expense and difficulty of doing these...trials for the most important diseases have become very hard and very difficult to the point that many of the big companies have actually gotten out of the field of antibiotic development because they don’t feel that it’s worth the investment," he said.

Some drug company executives contend that financial returns on investments made in a new antibiotic are significantly lower than for other new drugs reaching the market.

“Think about the cholesterol-lowering drug - it’s not uncommon for many of the statins to be bringing in $5 - 10 or more billions per year. For an antibiotic to sell at a half a billion is considered a blockbuster, almost unheard of," he said.

Eisenstein says the push to make "a perfect drug" that is both safe and effective beyond a shadow of doubt has considerably slowed the pace of new antibiotics reaching the market.

To get companies back in the antibiotics game, Eisenstein says two things have to be done.

“The regulatory risk - to decrease the great hurdles to get approval and increase the likelihood of being able to get a drug approved in a shorter period of time, at a higher proportion of probability. And then on the economic side, to enable the companies to have greater incentives to overcome what we call market failure," he said.

Drug companies note that the newest antibiotics, typically, are likely to be prescribed more carefully and used more sparingly - meaning slower sales and smaller profits for the companies that develop them.

Neverthless, public health experts say one new antibiotic has already been approved for use in the United States, and they are hopeful that the ambitious goal  of developing nine more by 2020 can be achieved.

You May Like

EU Court Fines Poland for Hosting CIA 'Black Sites'

Ruling is first time a court has acknowledged suspects were held and tortured at the sites, under US program launched following the 9/11 terrorist attacks More

Migrant Issues Close to Home Spur Groups to Take Action

Groups placing water, food in the desert, or aiding detainees after release, have one common goal: no more deaths of migrants crossing illegally into the US More

Video At AIDS Conference, Prevention Pill Stirs Excitement

Truveda shows promise, spurring debate over access and other approaches More

This forum has been closed.
Comments
     
There are no comments in this forum. Be first and add one

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Treatment for Childhood Epilepsy Heats up Medical Marijuana Debatei
X
Shelley Schlender
July 24, 2014 6:43 PM
In the United States, marijuana is classed as an illegal drug by the federal government. But nearly half the states have legalized it, to some degree. Proponents say some strains of marijuana might have exceptional health benefits, for treating pain or inflammation in chronic conditions such as cancer, multiple sclerosis and epilepsy. Shelley Schlender reports on a strain of medical marijuana developed in Colorado that is reputed to reduce seizures in childhood epilepsy
Video

Video Treatment for Childhood Epilepsy Heats up Medical Marijuana Debate

In the United States, marijuana is classed as an illegal drug by the federal government. But nearly half the states have legalized it, to some degree. Proponents say some strains of marijuana might have exceptional health benefits, for treating pain or inflammation in chronic conditions such as cancer, multiple sclerosis and epilepsy. Shelley Schlender reports on a strain of medical marijuana developed in Colorado that is reputed to reduce seizures in childhood epilepsy
Video

Video Airbus Adds Metal 3D Printed Parts to New Jets

By the end of this year, European aircraft manufacturing consortium Airbus plans to deliver the first of its new, extra-wide-body passenger jets, the A350-XWB. Among other technological innovations, the new plane will also incorporate metal parts made in a 3-D printer. VOA's George Putic has more.
Video

Video Death Toll From Israel-Gaza Conflict Surpasses 700

Gaza officials say a shelling hit a compound housing a United Nations-run school in the Gaza Strip, killing more than a dozen people, during an Israeli offensive in the area. Heavy fighting between the Israeli military and Hamas militants continued on Thursday, pushing up the death toll. So far, more than 730 Palestinians and 35 Israelis have been killed in the conflict. VOA's Scott Bobb has the latest from Jerusalem.
Video

Video AIDS Conference Welcomes Exciting Developments in HIV Treatment, Prevention

Significant strides have been made in recent years toward the treatment and prevention of HIV, the virus that causes AIDS. This year, at the International AIDS Conference, the AIDS community welcomed progress on a new pill that may prevent transmission of the deadly virus. VOA’s Anita Powell reports from Melbourne, Australia.
Video

Video Israel Targets Gaza Supply Tunnels

The Israeli military has launched a ground operation in Gaza to destroy the myriad tunnels that may have been used to smuggle weapons to Hamas. VOA's Zlatica Hoke reports that could mean more hardship for the people of Gaza, who obtain some of their essential supplies through these underground passages
Video

Video Researchers Target Low-Cost Avatar Technology

Scientists at the University of Southern California Institute for Creative Technologies say 3-dimensional representations could revolutionize social media. Elizabeth Lee has more from Los Angeles.
Video

Video IAEA: Iran Turns its Enriched Uranium Into Less Harmful Form

Iran has converted its stockpiles of enriched uranium into a less dangerous form that is more difficult to use for nuclear weapons, according to the United Nations’ Atomic Energy Agency. The move complies with an interim deal reached with Western powers on Iran's nuclear program last year, in exchange for easing of sanctions. Henry Ridgwell reports for VOA from London.
Video

Video In Cambodia, HIV Diagnosis Brings Deadly Shame

Although HIV/AIDS is now a treatable condition, a positive diagnosis is still a life altering experience. In Cambodia, people living with HIV are often disowned by friends, family and the community. This humiliation can be unbearable. We bring you one Cambodian woman’s struggle to overcome a life tragedy and her own HIV positive diagnosis.

AppleAndroid